Hereditary angioedema

Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization

Retrieved on: 
Wednesday, October 4, 2023
Seizure, Cardiac muscle, Progress, DSM-IV codes, American Medical Association, Journal, Patient, Division, ASO, Neurology, Disease, Columbia University, Tissue, Hypertriglyceridemia, Dementia, Small RNA, Ionis Pharmaceuticals, PDUFA, Pelizaeus–Merzbacher disease, FDA, FCS, Safety, Therapeutic index, Development, Alexander disease, IONS, MECP2, Medicine, HAE, MPH, JAMA, PLP1, Hereditary angioedema, Traffic barrier, RNA, AstraZeneca, Leukodystrophy, Delivery, Phase 3, Physician, World Creativity and Innovation Day, Vaccine, Pharmaceutical industry, Medical device, Residential care, Ionis, EU, ATTR

Presentations from Ionis leaders and external physicians will highlight Ionis' comprehensive integrated research, development, and commercialization capabilities, along with key pipeline and technology highlights.

Key Points: 
  • Presentations from Ionis leaders and external physicians will highlight Ionis' comprehensive integrated research, development, and commercialization capabilities, along with key pipeline and technology highlights.
  • "Our powerful and prolific research and development engine has discovered groundbreaking medicines for people with devastating diseases.
  • We have matched this engine with a talented commercial organization poised to deliver a steady flow of wholly owned medicines to patients.
  • The event will take place at the Westin New York Grand Central from 8:00 a.m. to 3:00 p.m. Eastern Time and will also be webcast.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Pharmaceutical, Health, Other Health, Allergy, Hereditary angioedema, Employment, Therapy, Pharmaceutical industry, Lease

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 61,000 shares of Astria’s common stock on October 2, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.

Key Points: 
  • Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 61,000 shares of Astria’s common stock on October 2, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.
  • The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.
  • The options were granted as an inducement material to three employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference

Retrieved on: 
Tuesday, September 19, 2023
Hereditary angioedema, HAE, Conference, Pharmaceutical industry, Online shopping

ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the 2023 Cantor Global Healthcare Conference, taking place in New York from September 26-28, 2023.

Key Points: 
  • ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the 2023 Cantor Global Healthcare Conference, taking place in New York from September 26-28, 2023.
  • Pharvaris management will participate in a fireside chat on Tuesday, September 26, from 2:10-2:40 p.m.
  • A live audio webcast of the 2023 Cantor Global Healthcare Conference fireside chat will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .
  • A replay will be available on Pharvaris’ website for 30 days following the presentation.

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Retrieved on: 
Monday, September 18, 2023
AOH, FRCP, Attack, Hereditary angioedema, BioCryst Pharmaceuticals, Doctor of Philosophy, RESEARCH, HAE, Patient, CADTH, Health Canada, PARK, Caregiver, Disease, Pharmaceutical industry

“While much progress has been made on behalf of the HAE community in Québec, people living with HAE continue to be in need of additional treatment options to help manage their HAE attacks.

Key Points: 
  • “While much progress has been made on behalf of the HAE community in Québec, people living with HAE continue to be in need of additional treatment options to help manage their HAE attacks.
  • Additionally, this recommendation is a step forward as it highlights the need for continued, and simple access for people living with HAE, and their caregivers,” said Charles St-Pierre, president of Hereditary Angioedema Québec (AOH Québec).
  • “As a physician who treats HAE patients, I see first hand how people respond to different HAE treatments, and not every patient’s experience is the same.
  • Health Canada authorized ORLADEYO in June 2022 for the routine prevention of recurrent HAE attacks in patients 12 years and older.

Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants

Retrieved on: 
Tuesday, September 19, 2023
Health, Infectious Diseases, Genetics, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Vaccine, Infection, European Scientific Cooperative on Phytotherapy, Diversified Specialty Institute Holdings, Inc., Influenza, Omicron, AE, Vaccination, SARS-CoV-2, Nephrology, SARS-CoV-2 Omicron variant, Public, Aes, Hereditary angioedema, Drug, Haemophilia, ARCT, CSL, Cell, RNA, Delta, Messenger, HAE, Iron deficiency, Patient, Beta, Liver, Poster, Immunodeficiency, Conference, North West Ambulance Service, B.1, Arcturus

Three sa-mRNA vaccines were used in the study, which was presented as a poster at the European Scientific Working Group on Influenza's 9th ESWI Influenza Conference in Valencia, Spain.

Key Points: 
  • Three sa-mRNA vaccines were used in the study, which was presented as a poster at the European Scientific Working Group on Influenza's 9th ESWI Influenza Conference in Valencia, Spain.
  • However, sa-mRNA also provides the body with instruction to make copies of the mRNA, amplifying the amount of protein made.
  • This advanced technology has shown the potential to offer longer duration of immune response at considerably lower doses compared to conventional mRNA vaccines.
  • Similar trends were observed for other SARS-CoV-2 variants including Beta, Delta, Omicron BA.1, Omicron BA.2, and Omicron BA.4/5.

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

Retrieved on: 
Friday, September 22, 2023
Hereditary angioedema, Face, Marketing, Safety, TAK, European Directive on Traditional Herbal Medicinal Products, Pharmacokinetics, European Medicines Agency, Clinical research associate, European Commission, Genetic disorder, First, Committee, EMA, SPRING, HAE, Patient, Committee for Medicinal Products for Human Use, Abdomen, Diagnosis, Ageing, Throat, Flint Adolescent Study, EC, NYSE, Combination, CHMP, Vaccine, Pharmaceutical industry, Lanadelumab, EU, Takeda

HAE is a Rare, Genetic Disorder Estimated to Affect About 1 in 10,000 to 1 in 50,000 People Worldwide.

Key Points: 
  • HAE is a Rare, Genetic Disorder Estimated to Affect About 1 in 10,000 to 1 in 50,000 People Worldwide.
  • The Condition Results in Recurring Attacks of Oedema (Swelling) in Various Parts of the Body that can be Debilitating and Painful.
  • [4],[5],[6] The European Commission (EC) will consider the CHMP positive opinion and decide upon potential marketing authorization in the coming months.
  • Lanadelumab is currently indicated for the routine prevention of recurrent attacks of HAE in patients aged 12 years and older.

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

Retrieved on: 
Thursday, September 7, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Injection, Attack, Stifel, Hereditary angioedema, NDA, Medication, Research, European Academy of Allergy and Clinical Immunology, HAE, Patient, Physician, Commercial, KALV, FDA, Conference, D, Pharmaceutical industry

(NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2023.

Key Points: 
  • (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2023.
  • First Fiscal Quarter Financial Results:
    Revenue: No revenue was recognized for the three months ended July 31, 2023 or July 31, 2022.
  • The increase in R&D expenses during the quarter primarily reflects the ongoing Phase 3 KONFIDENT trial for sebetralstat and increased personnel costs.
  • The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.

Astria Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, September 6, 2023
Health, Infectious Diseases, Health Technology, Health Insurance, Clinical Trials, Pharmaceutical, Biotechnology, Morgan Stanley, Allergy, Morgan, Hereditary angioedema, HAE, Therapy, Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will be participating in two upcoming investor conferences:

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will be participating in two upcoming investor conferences:
    Noah Clauser, Chief Financial Officer, will present a corporate overview and information on STAR-0215 at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12th at 10:00am ET in New York, NY.
  • Astria will be participating in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13th in New York, NY.
  • A webcast of the presentation at H.C. Wainwright can be accessed at the following link: https://journey.ct.events/view/8b0ad478-68ce-4168-8d0a-2383781f3a0c .
  • An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

Pharvaris To Present at the 18th German Allergy Congress

Retrieved on: 
Wednesday, September 6, 2023
Hereditary angioedema, Abstract, HAE, Congress, Safety, Pharmaceutical industry

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the 18th German Allergy Congress, taking place in Bonn, Germany, from September 14-16, 2023.

Key Points: 
  • ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the 18th German Allergy Congress, taking place in Bonn, Germany, from September 14-16, 2023.
  • Title: Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
    The abstracts will be published in the congress issue of the Allergo Journal International and Allergologie.
  • After the close of the ePoster session “Angioedema,” the posters will be made available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .

Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
Wednesday, September 6, 2023
Morgan Stanley, Morgan, Hereditary angioedema, HAE, Doctor of Philosophy, Conference, Pharmaceutical industry, Online shopping, Cryptocurrency

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the Morgan Stanley 21st Annual Global Healthcare Conference, taking place in New York from September 11-13, 2023.

Key Points: 
  • ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the Morgan Stanley 21st Annual Global Healthcare Conference, taking place in New York from September 11-13, 2023.
  • Morgan Conn, Ph.D., Chief Business Officer of Pharvaris, will participate in a fireside chat on Monday, September 11, at 3:35 p.m.
  • A live audio webcast of the Morgan Stanley 21st Annual Global Healthcare Conference fireside chat will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .
  • A replay will be available on Pharvaris’ website for 30 days following the presentation.